What's new in the diagnosis and treatment of cutaneous malignancy
In this medfyle
Expert commentary by Aaron R Mangold, MD
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Acknowledgements
This is a highlights summary of an oral session given at the AAD Virtual Meeting Experience 2021 and presented by:
Darrell S. Rigel, MD, FAAD
New York Grossman School of Medicine, New York, NY, USA
The content is produced by Infomedica, the official reporting partner of AAD VMX 2021. The summary text was drafted by Marie Farrow for Medfyle, and reviewed by Martina Lambertini, MD, an independent external expert, and approved by Hassan Galadari, MD, FAAD, the scientific editor of the program.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
In addition, an expert commentary on the topic has been provided by:
Aaron R Mangold, MD
Mayo Clinic Arizona
About the Expert
Aaron R Mangold, MD
Mayo Clinic Arizona
Assistant Professor of Dermatology, Chair of the Division of Medical Dermatology at Mayo Clinic in Arizona, USA. Director of multidisciplinary cutaneous lymphoma and clinical trials unit with an emphasis on novel therapeutics in inflammatory diseases and cutaneous lymphoma. Research group is focused on translational studies in cancer diagnosis, prognosis, and novel therapeutics. Established large, well-annotated databases in cSCC, cutaneous lymphoma, acral melanoma, and cutaneous granulomas. PI on multiple ongoing clinical trials and basic science studies in the clonal evolution of malignancy as it pertains to cutaneous lymphoma, melanoma, and cSCC. Past president of the state dermatology society in Arizona. In this role, our team was awarded multiple grants and have successfully lobbied for skin cancer prevention measures for minors. These efforts complement my scientific endeavors to reduce the incidence, mortality, and morbidity of skin cancer.
References
1. Marson JW, Litchman GH, Rigel DS. The magnitude of increased US melanoma incidence attributable to ground-level ultraviolet radiation intensity levels. J Am Acad Dermatol 2020;S0190-9622(20)32497-X.
2. O'Sullivan DE, Brenner DR, Demers PA, et al. Indoor tanning and skin cancer in Canada: A meta-analysis and attributable burden estimation. Cancer Epidemiol 2019;59:1–7.
3. Friedman RJ, Rigel DS, Kopf AW. Early detection of malignant melanoma: The role of physician examination and self-examination of the skin. CA Cancer J Clin 1985;35(3):130–51.
